Voya Investment Management LLC Has $40.33 Million Stake in Natera, Inc. $NTRA

Key Points

• Voya Investment Management LLC reduced its stake in Natera, Inc. by 36.4% in Q1, owning approximately 0.21% of the company, valued at $40.33 million.
• Natera reported a loss per share of $0.74 for the last quarter, missing estimates, but achieved a 32.2% increase in year-over-year revenue, totaling $546.6 million.
• Institutional investors own a significant majority of Natera, with approximately 99.90% of its stock, reflecting strong interest from the investment community.

Voya Investment Management LLC decreased its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 36.4% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 285,197 shares of the medical research company's stock after selling 163,083 shares during the period. Voya Investment Management LLC owned about 0.21% of Natera worth $40,330,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Strs Ohio acquired a new stake in shares of Natera during the 1st quarter valued at $8,992,000. Geneos Wealth Management Inc. boosted its stake in shares of Natera by 142.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,098 shares of the medical research company's stock valued at $155,000 after buying an additional 646 shares during the period. IFM Investors Pty Ltd acquired a new stake in shares of Natera during the 1st quarter valued at $3,498,000. Intech Investment Management LLC boosted its stake in shares of Natera by 591.4% during the 1st quarter. Intech Investment Management LLC now owns 85,369 shares of the medical research company's stock valued at $12,072,000 after buying an additional 73,021 shares during the period. Finally, Focus Partners Wealth boosted its stake in shares of Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock valued at $847,000 after buying an additional 474 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Transactions at Natera

In related news, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This trade represents a 31.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 6,092 shares of Natera stock in a transaction on Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $851,722.52. Following the completion of the transaction, the chief executive officer owned 169,400 shares in the company, valued at $23,683,814. This trade represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,423 shares of company stock worth $8,459,656. Corporate insiders own 5.63% of the company's stock.

Natera Price Performance

Shares of NTRA opened at $168.51 on Friday. The company has a market capitalization of $23.13 billion, a PE ratio of -88.23 and a beta of 1.68. Natera, Inc. has a one year low of $117.27 and a one year high of $183.00. The company's fifty day moving average price is $155.18 and its 200 day moving average price is $154.13.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business's revenue was up 32.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NTRA. Cowen reissued a "buy" rating on shares of Natera in a research note on Friday, August 8th. Stephens reissued an "overweight" rating and set a $183.00 target price on shares of Natera in a research note on Friday, August 15th. Barclays reaffirmed an "overweight" rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Finally, Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $194.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.